Document:

EX-10.4

 Exhibit 10.4 

COLLABORATION AGREEMENT 

THIS COLLABORATION AGREEMENT (this
“Agreement”) is made and entered into this 1st of June, 2018 (the “Effective Date”), by and between Urovant Sciences GmbH (“Urovant”), a
Switzerland limited liability company with an address of 8 Viaduktstrasse, 4051 Basel, Switzerland, and Roivant Sciences GmbH (“Roivant”), a Switzerland limited liability company with an address of 8 Viaduktstrasse,
4051 Basel, Switzerland. Urovant and Roivant are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. 

RECITALS 

WHEREAS, Urovant in-licensed certain intellectual property rights
from Merck (as defined below) pursuant to the Merck Agreement (as defined below) in all countries of the world outside of the Kyorin Territory (as defined below) with respect to Licensed Compounds and Products (both as defined below); 

WHEREAS, prior to entering into the Merck Agreement, Merck entered into an agreement with Kyorin (defined
below) for the grant of intellectual property rights with respect to the Product for the Kyorin Territory; 

WHEREAS, after entering into the Merck Agreement, Urovant and Kyorin entered into the Kyorin Agreement
(as defined below) in order to exchange information on the development and commercialization of Licensed Compounds and Products in their respective territories; 

WHEREAS, Urovant has certain obligations both to Merck with respect to such intellectual property rights
arising from the conduct of development or commercialization of products in China, and to Kyorin pursuant to the Kyorin Agreement; 

WHEREAS, Urovant and its Affiliate Roivant entered into the Roivant Agreement (as defined below), whereby
Urovant assigned to Roivant the Merck Agreement and its rights related thereto solely as they relate to China; 

WHEREAS, Roivant and its Affiliate SSL (as defined below) entered into the Sinovant Agreement (as defined
below), whereby Roivant assigned to SSL, inter alia, its rights under the Roivant Agreement in China; 

WHEREAS, SSL and its wholly owned subsidiary SinoHK (as defined below) entered in the Sinovant Sublicense
(as defined below), whereby SSL sublicensed to SinoHK, inter alia, its intellectual property rights under the Sinovant Agreement in China, Taiwan, Macau, Hong Kong, and South Korea; and 

WHEREAS, Urovant and Roivant, on behalf of its Affiliates, desire to enter into this Agreement to
coordinate their activities with respect to development of and the sharing of information regarding Licensed Compounds and Products in their respective territories and to clarify their respective responsibilities to Merck and Kyorin with respect to
Licensed Compounds and Products; 

  
 [***] = Portions of this exhibit
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 NOW THEREFORE, in consideration of the mutual
agreements, covenants and considerations contained herein, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows: 

ARTICLE 1 

DEFINITIONS 

As used in this Agreement, all capitalized terms, whether used in the singular or plural form, will have the meanings set forth below or in
the Agreement. 
 1.1    “Affiliate” means, with respect to a given Party, any entity that,
directly or indirectly, through one or more intermediaries, is controlled by, controlling, or under common control with such Party, as the case may be, but for only so long as such control exists. As used in this Section 1.1,
“control” shall mean direct or indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the voting share
capital or other equity interest in any entity. 
 1.2    “Confidential Information” shall mean
(i) information not in the public domain that is disclosed by one Party or its Affiliates to the other Party or its Affiliates, including all data and information relating to any Licensed Compound or Product, or the business, marketing,
promotion, affairs, research and development activities, results of clinical studies, national and multinational regulatory proceedings and affairs, finances, manufacturing, plans, contractual relationships and operations of either Party or their
Affiliates which is disclosed or provided by or on behalf of one Party to the other Party in connection with this Agreement and (ii) the terms and conditions contained in this Agreement that are not in the public domain. 

1.3    “Kyorin” means Kyorin Pharmaceutical Co., Ltd., having a place of business at 6, Kanda
Surugadai 4-chome, Chiyoda-ku, Tokyo, 101-8311, Japan. 

1.4    “Kyorin Agreement” means the Collaboration Agreement by and between Urovant and Kyorin,
dated August 24, 2017. 
 1.5    “Kyorin Territory” means Japan, Brunei, Cambodia, Hong
Kong, Indonesia, Korea, Laos, Malaysia, Myanmar, Philippines, Singapore, Taiwan, Thailand and Vietnam. 

1.6    “Licensed Compound” shall have the meaning assigned to it under the Merck Agreement. 

1.7    “Merck” means Merck Sharpe & Dohme, Corp., a corporation organized and existing
under the laws of the State of New Jersey, Unites States of America. 
 1.8    “Merck Agreement”
means the License Agreement by and between Merck and Urovant, dated February 3, 2017, as amended on April 27, 2017, and as may be further amended from time to time, [a copy of which is attached hereto as Appendix A]. 

  
 2 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 1.9    “Merck Indemnitees” shall have the meaning
assigned to it under the Merck Agreement. 
 1.10    “Merck Intellectual Property” shall have
the meaning assigned to it under the Merck Agreement 
 1.11    “Merck Patent Rights” shall have
the meaning assigned to it under the Merck Agreement. 
 1.12    “Product” means any and all
pharmaceutical products with any kinds of strength, dosage form, and formulations containing Vibegron or any other Licensed Compound as an active pharmaceutical ingredient, either alone or in combination with one or more other active pharmaceutical
ingredient(s). 
 1.13    “Roivant Agreement” means the China IP Purchase Agreement by and
between Urovant and Roivant, dated as of June 12, 2017, as amended on May 22, 2018. 

1.14    “Sinovant Agreement” means the China and South Korea IP Purchase Agreement by and between
Roivant and SSL, dated as of February 14, 2018. 
 1.15    “Sinovant Sublicense” means the
Intellectual Property License Agreement by and between SSL and SinoHK, dated as of March 16, 2018. 

1.16    “SinoHK” means Sinovant Sciences HK Limited (registration number 2639646), with a
registered office at 9/F Three Exchange Square, Central, Hong Kong. 
 1.17    “SSL” means
Sinovant Sciences Ltd., a Bermuda exempted limited company with an address at Clarendon House, 2 Church Street, Hamilton HM11 Bermuda. 

1.18     “Transferee” means any of Roivant’s assignees, licensees, sublicensees or any other
Party that receives or benefits from Roivant’s rights under the Merck Agreement, whether directly or indirectly, to develop and commercialize any Product in China. For clarity, without limiting the generality of the foregoing, SSL and SinoHK
shall be deemed Transferees for the purposes of this Agreement. 
 1.19    “Third Party” means a
person or entity other than Urovant or Roivant, or any of their Affiliates. 

1.20    “Vibegron” means the chemical compound identified as [***]. 

ARTICLE 2 

DEVELOPMENT AND COMMERCIALIZATION ACTIVITIES 

2.1    Development Plan. Roivant shall, or it shall use diligent efforts to require that its Transferees
shall, conduct all development activities with respect to any Licensed Compounds or Products in China pursuant to a development plan (“Development Plan”), which includes, without 

  
 3 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 
limitation, (i) the proposed overall development program for the applicable Licensed Compound or Product and indications in China, including
non-clinical studies, clinical trials, toxicology, formulation, and regulatory plans; and (ii) the anticipated timelines of any non-clinical studies, clinical
trials, chemistry, manufacturing and controls development activities, and regulatory meetings and filings. As between the Parties, Roivant and its Transferees shall retain control over all development activities of Products in and for China;
provided, that Roivant shall, or shall use diligent efforts to cause its Transferees to, promptly provide to Urovant a copy of the Development Plan and any material amendments thereto upon Urovant’s written request no more than once per
year, and consider in good faith any of Urovant’s comments thereto. Urovant shall have the right to share the contents of the Development Plan with Merck, solely to the extent necessary to fulfill its reporting obligations under the Merck
Agreement. Notwithstanding the foregoing, if Urovant reasonably determines that any such proposed development activities pose a reasonable likelihood of resulting in a material adverse effect on the development or commercialization of Products
outside of China, Urovant and Roivant, or its Transferee as the case may be, shall convene and discuss in good faith a reasonable resolution to such matter; provided, that Roivant shall retain ultimate decision making authority over such
matter. 
 2.2    Cross Territorial Restrictions. Roivant hereby covenants and agrees that it shall not,
and shall ensure that its Transferees will not, either directly or indirectly, promote, market, distribute, import, sell or have sold the Product (or any Licensed Compound), including via internet or mail order, into countries outside China. As to
such countries outside China (which are exclusively reserved for Urovant), Roivant shall not, and shall ensure that its Transferees will not: (b) engage in any advertising or promotional activities relating to the Product (or any Licensed
Compound) that are directed primarily to customers or other purchaser or users of the Product (or any Licensed Compound) located in such countries, (c) solicit orders for the Product (or any Licensed Compound) from any prospective purchaser
located in such countries, or (d) sell or distribute the Product (or any Licensed Compound) to any person in China who Roivant or its Transferees have reason to believe intends to sell or has in the past sold the Product (or any Licensed
Compound) in such countries. If Roivant or any of its Transferees receives any order for the Product (or any Licensed Compound) from a prospective purchaser located in a country outside China, Roivant shall immediately refer that order to Urovant
and neither Roivant nor any such Transferee shall accept any such orders. Neither Roivant nor any Transferee shall deliver or tender (or cause to be delivered or tendered) the Product (or any Licensed Compound) into a country outside China. Both
Parties shall not, and shall ensure that its Transferees will not, restrict or impede in any manner the other Party’s exercise of its exclusive rights. Roivant will, and shall ensure that its Transferees will, use its reasonable commercial
efforts to establish and maintain a secure supply chain and to ensure that the Product (or any Licensed Compound) is not diverted outside of China. Roivant will, and shall ensure that its Transferees will, reasonably assist Urovant in any
investigation relating to the diversion of Product (or any Licensed Compound) from China to countries outside China, including by using reasonable efforts to provide Urovant with a list of any of its distributors, wholesalers, and suppliers of
Product (and any Licensed Compound). 

  
 4 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 ARTICLE 3 

INFORMATION SHARING; SAFETY DATA 

3.1    Information Sharing. Roivant hereby acknowledges that Urovant is subject to certain information
sharing obligations pursuant to the Kyorin Agreement that relate to or include or involve the development of Vibegron in countries outside the Kyorin Territory, including China. Roivant shall, or shall use diligent efforts to cause its Transferees
to, promptly provide to Urovant any information required for Urovant to satisfy its obligations under the Kyorin Agreement, upon Urovant’s reasonable request following Kyorin’s request to Urovant; provided, that such obligation
shall not pertain to any information relating to CMC or manufacturing of Vibegron or any Product, except as agreed by Roivant or such Transferee, and Roivant and its Transferees shall not be obligated to translate any such information or provide any
original hardcopy or original files containing any such information. Urovant hereby agrees to provide to Roivant or its Transferees any information Urovant receives from Kyorin with respect to Vibegron pursuant to the Kyorin Agreement upon
Roivant’s or its Transferee’s reasonable request (provided, that Urovant shall not be obligated to provide such information in a form other than in which Urovant received it). Urovant further agrees to request information from Kyorin
pursuant to the Kyorin Agreement upon Roivant’s or its Transferee’s reasonable request. 

3.2    Safety Database; Pharmacovigilance Agreement. The Parties hereby agree that, consistent with
Section 8.3 of the Merck Agreement, Urovant shall maintain a global safety database for the Products. Roivant shall, or shall use diligent efforts to cause its Transferee to, periodically (and in any event no less than once a calendar quarter)
report to Urovant any safety data generated in China with respect to any Product during such reporting period; provided, that upon the occurrence of any material safety adverse event with respect to Products in China, Roivant shall, or shall
use diligent efforts to cause its Transferee to, promptly (and in any event no more than two (2) days thereafter) notify Urovant of such event and provide any relevant information thereto as reasonably requested by Urovant. Upon reasonable
request by Roivant or its Transferee, Urovant shall provide Roivant or its Transferee with reasonable access to the global safety database. Within sixty (60) days of this Agreement, Urovant and Roivant (or its Transferee) shall execute a
pharmacovigilance agreement on reasonable and customary terms (“Pharmacovigilance Agreement”) that shall provide, among other things, guidelines and responsibilities for (a) the receipt, investigation, recording, review,
communication, reporting, and exchange between such Parties of adverse event reports and other safety information relating to the Product such as CCDSs, safety signaling, core-RMP, periodic / aggregate reports
(DSUR, PBRER) without any consideration; (b) appropriate reconciliation procedures to ensure adequate and compliant exchange of safety data; (c) contact with government authorities with respect to the foregoing; and (d) Urovant’s
maintenance of a global safety database with respect to the Product at its cost; in each case (a)-(d), in accordance with applicable law. The Pharmacovigilance Agreement shall contain terms no less stringent than those required by ICH or other
applicable guidelines to allow the Parties to meet the applicable regulatory and legal requirements regarding the management of safety data in their respective territories. 

3.3    Right of Reference. Urovant hereby grants Roivant or its Transferee access to, and a right of
reference with respect to, all regulatory materials controlled by Urovant with respect to 

  
 5 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 
any Product and corresponding documentation, solely for the purposes of (a) commercializing any Product in China, and (b) developing or manufacturing any Product in China (including the
use for any meeting with or any submission to the relevant government authority for the purpose of obtaining any regulatory approvals of any Product for any indication), in each case, in accordance with all applicable laws. Roivant hereby grants to
Urovant (and its Affiliates and sublicensees) access to, and a right of reference with respect to, all regulatory materials controlled by Roivant or its Transferees and corresponding documentation, for the purposes of (i) commercializing any
Product outside of China, and (ii) developing or manufacturing any Product outside of China (including the use for any meeting with or any submission to the relevant government authority for the purpose of obtaining any regulatory approvals of
any Product for any indication), in each case, in accordance with all applicable laws. 
 ARTICLE 4 

CONFIDENTIALITY 

4.1    Confidential Information. All Confidential Information disclosed by Roivant, any Transferee, or
Urovant (“Disclosing Party”) to the other Party or its Transferees (“Receiving Party”) hereunder shall be maintained in confidence by the Receiving Party and shall neither be disclosed to any Third Party (other than
Merck or Kyorin as provided for in this Agreement or the Merck Agreement) nor used for any purpose except as set forth herein without the prior written consent of the Disclosing Party, except as provided in Sections 4.2 and 4.3, and except to
the extent that such Confidential Information: 
 (a)    is known by the Receiving Party at the time of its
receipt, and not through a prior disclosure by the Disclosing Party, as documented by the Receiving Party’s business records; 

(b)    is properly in the public domain by use and/or publication before its receipt from the Disclosing Party, or
thereafter enters the public domain through no fault of the Receiving Party; 
 (c)    is subsequently disclosed
to the Receiving Party by a Third Party who may lawfully do so and is not under an obligation of confidentiality to the Disclosing Party; or 

(d)    is independently developed by the Receiving Party without use of or reference to the Confidential Information
received from the Disclosing Party, as documented by the Receiving Party’s business records. 

4.2    Permitted Disclosure. Notwithstanding the foregoing, the Receiving Party may disclose the
Confidential Information of the Disclosing Party to: 
 (a)    its Affiliates, actual or potential sublicensees,
business partners, subcontractors, employees, consultants, agents, and advisors solely on a “need to know” basis, each of whom prior to disclosure must be bound by obligations of confidentiality and
non-use of such Confidential Information no less restrictive than those set forth in this Article 4; and 

  
 6 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 (b)    actual or potential investors, investment bankers, lenders,
other financing sources or acquirors (and attorneys and independent accountants thereof) in connection with potential investment, acquisition, collaboration, merger, public offering, due diligence or similar investigations by such Third Parties or
in confidential financing documents, provided, in each case, that any such Third Party agrees to be bound by terms of confidentiality and non-use (or, in the case of the Receiving Party’s attorneys
and independent accountants, such Third Party is obligated by applicable professional or ethical obligations) that are no less stringent than those contained in this Agreement (except to the extent that a shorter confidentiality period is customary
in the industry). 
 4.3    Compelled Disclosure. If Receiving Party becomes legally compelled to disclose
any Confidential Information, other than pursuant to a confidentiality agreement, Receiving Party will provide Disclosing Party prompt written notice of such disclosure and will assist Disclosing Party in seeking a protective order or another
appropriate remedy. If Disclosing Party waives Receiving Party’s compliance with this Agreement or fails to obtain a protective order or other appropriate remedy, Receiving Party will furnish only that portion of the Confidential Information
that is legally required to be disclosed as advised by outside counsel; provided, that any Confidential Information so disclosed shall maintain its confidentiality protection for all purposes other than such legally compelled disclosure. 

4.4    Publication. If Roivant or its Transferees wish to submit any publications disclosing the results of
studies carried out with respect to the Product in China, it shall provide Urovant with the opportunity to review and comment on any proposed publication which relates to the Product at least thirty (30) days prior to its intended submission
for publication. Roivant and its Transferees shall: (a) consider in good faith any comments thereto provided by Urovant within such thirty (30) day period; and (b) remove any Confidential Information of Urovant identified by Urovant
as part of its review. 
 ARTICLE 5 

INTELLECTUAL PROPERTY 

5.1    Roivant or its Transferee shall have the right to exercise the rights of Urovant under the Merck Agreement
to undertake to file, prosecute and maintain the Merck Patent Rights in China, and at its sole cost; provided, that Roivant shall, or shall use diligent efforts to cause its Transferee to, coordinate with Urovant with respect to any such
filings or other interactions with patent offices in China and consider in good faith any comments raised by Urovant, and in the event Roivant or its designated Transferee does not elect to so file or prosecute or maintain any such Merck Patent
Rights, it shall inform Urovant and provide it with at least forty-five (45) days prior notice of any impending deadline and Urovant shall have the right, at its expense, to assume responsibility for such filings and maintenance, and if it does
not exercise such right, then Merck shall have such right, consistent with the Merck Agreement. 
 5.2    Roivant
shall, or shall use diligent efforts to cause its Transferees to, inform Urovant within five (5) business days of learning of any request for, or filing or declaration of, any interference, derivation, opposition, reexamination, or post grant
review or similar proceedings or notice from a Third Party indicating the possibility of any such action relating to any Merck Patent 

  
 7 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 
Right in China. Roivant or its designated Transferee shall have the first right to control the defense of such action at its own expense and shall permit Urovant, or Merck as the case may be, to
participate in such action. If Roivant does not wish to proceed with the defense of any such action, it shall notify Urovant in writing and Urovant, or Merck, if Urovant does not exercise such right, shall have the right to so defend such action,
consistent with the Merck Agreement. 
 5.3    Roivant or its Transferee shall have the first right to take any
actions to enjoin any and all infringements or unauthorized uses of the Merck Intellectual Property in China, including the right to settle any such action; provided, that it shall not settle any such action in a manner that would impose any
restrictions on Urovant’s ability to develop or commercialize Products in the rest of the world outside of the Kyorin Territory, without the consent of Urovant. If Roivant or its Transferee fails to assume such control of such action within the
earlier of (i) ten (10) calendar days after service of the complaint in such action, or (ii) ten (10) calendar days prior to any date any answer or other response is due in connection with any such action, Urovant or Merck, if Urovant does
not exercise such right, shall have the right to assume direction and control thereto, at its cost and expense. Urovant shall not settle any such action in a manner that would impose any restrictions on Roivant’s or its Transferee’s
ability to develop or commercialize Products in China, without the consent of Roivant and its Transferee. 
 ARTICLE 6 

INDEMNIFICATION; TERMINATION OF MERCK AGREEMENT 

6.1    Urovant shall and hereby does agree to indemnify and to hold Roivant and its Transferee harmless against any
and all losses, damages, liabilities, expenses and costs, including reasonable attorneys’ fees, which Roivant or such Transferee may become subject to as a result of any claims, suits, actions or proceedings by Merck arising from, relating to,
or attributable to the breach by Urovant of any of its payment or other obligations to Merck (other than any such breach caused by any failure of Roivant to pay or to cause to be paid to Urovant any milestones or royalties arising from the
development or commercialization of Products in China required to be paid pursuant to the Roivant Agreement). 

6.2    Roivant shall or shall cause its Transferee to, indemnify directly, on behalf of Urovant, the Merck
Indemnitees from any and all losses arising from Third Party claims resulting from any breach by Roivant or any Transferee of its obligations as an assignee of the Merck Agreement with respect to China, or the development or commercialization of the
Products in China, or its negligence or willful misconduct in exercising such rights or obligations (a “China Based Claim”), all as further provided in and in accordance with Section 13.2 of the Merck Agreement. In the event any China
Based Claim for indemnification is brought by any Merck Indemnitee against Urovant under the Merck Agreement, Urovant shall promptly provide such notice to Roivant or its Transferee, in which event Roivant or such Transferee, and not Urovant, shall
be solely responsible for the investigation, defense, settlement and discharge of such claim all as provided in Section 13.2 of the Merck Agreement, applied mutatis mutandis. 

6.3    Urovant agrees that it shall not exercise any unilateral termination rights with respect to the Merck
Agreement as they relate to any Licensed Compound or Product in China 

  
 8 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 
unless directed to do so in writing by Roivant or its Transferee. Roivant agrees that it shall not, and shall use diligent efforts to cause its Transferees not to, exercise any unilateral
termination rights with respect to the Merck Agreement as they relate to any Licensed Compound or Product in China until it first provides Urovant written notice thereof, in which event Urovant shall have the right to
re-acquire from Roivant such rights, on terms to be agreed upon by the Parties. 

6.4    The term of this Agreement shall extend until the termination or expiration of the Merck Agreement by either
Party as it relates to its territory, or the cessation of all Licensed Compounds and Products by a Party, whichever occurs later. 

ARTICLE 7 

MISCELLANEOUS 

7.1    No Implied Licenses. No license or other right is or shall be created or granted hereunder by
implication, estoppel, or otherwise. All rights are or shall be granted only as expressly provided in this Agreement. 

7.2    Mutual Representations, Warranties and Covenants. Each of the Parties hereby represents and warrants
to the other Party as of the Effective Date and covenants that: 
 (a)    Organization. It is a corporation
duly organized, validly existing, and in good standing under the laws of the jurisdiction of its organization, and has all requisite power and authority, corporate or otherwise, to execute, deliver, and perform this Agreement. 

(b)    Binding Agreement. This Agreement is a legal and valid obligation binding upon such Party and
enforceable in accordance with its terms. 
 (c)    Authorization. The execution, delivery, and performance
of this Agreement by such Party have been duly authorized by all necessary corporate action and do not conflict with any agreement, instrument, or understanding, oral or written, to which it is a party or by which it is bound, nor violate any
Applicable Law or any order, writ, judgment, injunction, decree, determination, or award of any court or governmental body, or administrative or other agency presently in effect applicable to such Party. 

(d)    No Inconsistent Obligations. Neither Party is under any obligation, contractual or otherwise, to any
Person that conflicts with or is inconsistent in any material respect with the terms of this Agreement, or that would impede the diligent and complete fulfillment of its obligations hereunder. 

7.3    No Other Representations or Warranties. NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY
WARRANTIES OR CONDITIONS OF ANY KIND, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT. ANY INFORMATION PROVIDED PURSUANT TO THIS AGREEMENT IS MADE AVAILABLE ON AN “AS IS” BASIS
WITHOUT WARRANTY WITH RESPECT TO ACCURACY, COMPLETENESS, COMPLIANCE WITH REGULATORY STANDARDS OR REGULATIONS OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER KIND OF WARRANTY WHETHER EXPRESS OR IMPLIED. 

  
 9 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 7.4    Assignment. Neither Party may assign or transfer this
Agreement or any rights or obligations hereunder without obtaining the prior written consent of the other Party, except that each Party may assign its rights and obligations under this Agreement in whole or in part to one or more of its Affiliates
without the consent of the other Party. Any permitted assignment shall be binding on the successors of the assigning Party. Any assignment or attempted assignment by either Party in violation of the terms of this Section 7.4 shall be null, void
and of no legal effect. 
 7.5    Notices. Any notice to be given under this Agreement must be in writing
and delivered either in person, or by (a) air mail (postage prepaid) requiring return receipt, (b) international courier, or (c) e-mail to the Party to be notified at its address(es) given
below, with delivery and read receipts requested, or at any address such Party may designate by a prior written notice to the other Party in accordance with this Section 7.5. Notice shall be deemed sufficiently given for all purposes upon:
(i) if by air mail or courier, the date of actual receipt; or (ii) if by e-mail, the date of confirmation of receipt by the intended recipient. Notices shall be sent to: 

 

			
	For Urovant:	  	Urovant Sciences GmbH
		  	8 Viaduktstrasse
		  	4051Basel, Switzerland
		  	Attention: VP, Head of Global Transactions
		
	With Copy To:	  	Urovant Sciences, Inc.
		  	5151 California Avenue, Suite 250
		  	Irvine, CA 92617
		  	Attention: General Counsel
		  	Bryan.Smith@Urovant.com
		
	For Roivant:	  	Roivant Sciences GmbH
		  	8 Viaduktstrasse
		  	4051 Basel, Switzerland
		  	Attention: VP, Head of Global Transactions
		
	With Copy To:	  	Roivant Sciences, Inc.
		  	320 West 37th Street, 6th Floor
		  	New York, NY 10018
		  	Attention: Legal Department
		  	Email: legalteam@roivant.com

 7.6    Entire Agreement. This Agreement and the Appendixes attached
hereto and made a part hereof contain every obligation and understanding between the Parties relating to the subject hereof and merge all prior discussions, negotiations and agreements between them, and none of the Parties shall be bound by any
conditions, definitions, understandings, warranties or representations other than as expressly provided or referred to herein. 

  
 10 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 7.7    Severability. If any one or more of the provisions of
this Agreement is held to be invalid or unenforceable by any court of competent jurisdiction from which no appeal can be or is taken, the provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining
provisions hereof. The Parties shall make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable provision such that the objectives contemplated by the Parties when entering this Agreement may be realized.

 7.8    Waiver and Non-Exclusion of Remedies. Any term or
condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving such term
or condition. The waiver by either Party hereto of any right hereunder or of the failure to perform or of a breach by the other Party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by such other Party
whether of a similar nature or otherwise. The rights and remedies provided herein are cumulative and do not exclude any other right or remedy provided by Applicable Law or otherwise available except as expressly set forth herein. 

7.9    Governing Law. This Agreement was prepared in the English language, which language shall govern the
interpretation of, and any dispute regarding, the terms of this Agreement or the Party’s respective performance hereunder. This Agreement and all disputes arising out of or related to this Agreement or any breach hereof shall be governed by and
construed under the laws of New York, without giving effect to any choice of law principles that would require the application of the laws of a different country. 

7.10    Dispute Resolution. Any dispute, claim or controversy arising out of or in connection with this
Agreement shall be finally resolved through arbitration under the Commercial Arbitration Rules of the American Arbitration Association in force as of the date of this Agreement. The place of arbitration shall be New York, and the arbitration shall
be conducted in the English language. The award issued by the sole arbitrator shall be final and binding upon the parties and shall not be subject to appeal. 

7.11    Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may be executed by facsimile, .pdf or other electronically transmitted signatures and such signatures shall be deemed to bind each Party
hereto as if they were the original signatures. 
 [REMAINDER OF PAGE
INTENTIONALLY LEFT BLANK] 

  
 11 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed as of the
Effective Date, by their duly authorized representatives. 
  

									
	UROVANT SCIENCES GMBH	 		 	ROIVANT SCIENCES GMBH
					
	By:	 	/s/ Sascha Bucher	 		 	By:	 	/s/ Ruben Masar
	Name:	 	Sascha Bucher	 		 	Name:	 	Ruben Masar
	Title:	 	Managing Director	 		 	Title:	 	Secretary of the Board

  
 12 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406.EX-10.5

 Exhibit 10.5 

EXECUTION VERSION 
 ENZYME SUPPLY
AGREEMENT 
 THIS ENZYME SUPPLY AGREEMENT, including the exhibits attached hereto (the “Agreement”),
effective as of September 01, 2017 (the “Effective Date”), is made and entered into by and between Codexis, Inc., a Delaware corporation, having a place of business at 200 Penobscot Drive, Redwood City, California
94063, United States of America (“Codexis”), and Urovant Sciences GmbH, a Swiss corporation, having a place of business at Viaduktstrasse 8, 4051 Basel, Switzerland (“Customer”). Codexis and
Customer each may be referred to herein individually as a “Party,” or collectively as the “Parties.” 

WHEREAS, Codexis has proprietary rights in certain enzymes, chemical synthesis and biocatalysis process technology, and possesses
certain valuable business and/or technical knowledge, information, and/or expertise, relating to enzymatically catalyzed manufacturing processes; 

WHEREAS, Customer is engaged in the business of manufacturing and supplying pharmaceutical ingredients and intermediates thereof and
has proprietary rights in certain compounds, including the Product, methods of manufacturing the Product and methods of use of the Product; 

WHEREAS, Customer is a licensee of certain intellectual property from Merck, Sharp & Dohme Corp.
(“MSD”) relating to the manufacture, sale and distribution of Product in the Territory; 
 WHEREAS, Codexis
desires to supply Codexis Enzyme to Customer, and Customer desires to use such Codexis Enzyme in the manufacture and supply of Product to customers in the Territory, as more fully set forth in this Agreement. 

NOW, THEREFORE, in consideration of the mutual covenants and obligations set forth herein, and for other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows: 
  

	1.	DEFINITIONS 

 1.1    “Affiliate”
shall mean any entity that is controlled by, controls, or is under common control with a Party on or after the Effective Date, as the case may be. For purposes of this Section 1.1, the term “control” means (a) direct or indirect
ownership of more than fifty percent (50%) of the voting interest in the entity in question, or more than fifty percent (50%) interest in the income of the entity in question; provided, however, that, if local law requires a minimum
percentage of local ownership of greater than fifty percent (50%), control will be established by direct or indirect beneficial ownership of one hundred percent (100%) of the maximum ownership percentage that may, under local law, be owned by
foreign interests, or (b) possession, directly or indirectly, of the power to direct or cause the direction of management or policies of the entity in question (whether through ownership of securities or other ownership interests, by contract
or otherwise). 

  
 -1- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 EXECUTION VERSION 
  

 1.2    “Agency” shall mean any applicable
local, national or supranational government regulatory authority involved in granting approvals for the manufacturing, marketing and/or pricing of Product. “Agencies” is the plural of Agency. 

1.3    “Applicable Law” shall mean all laws, statutes, ordinances, codes, rules, and
regulations that have been enacted by a Government Authority and are in force as of the Effective Date or come into force during the Term, in each case to the extent that the same are applicable to the performance by the Parties of their respective
obligations under this Agreement. 
 1.4    “Calendar Year” shall mean any twelve
(12) consecutive month period commencing on January 1 and ending December 31 during the Term. For example, Calendar Year 2017, for purposes of this Agreement, shall mean the period from January 1, 2017 through
December 31, 2017. 
 1.5    “Claims” shall have the meaning set
forth in Section 10.1. 
 1.6    “Codexis Enzyme” shall mean Codexis’ [***].

 1.7    “Codexis Inventions” shall mean any discovery, invention, contribution, method,
finding or improvement, whether or not patentable, and all related intellectual property, including without limitation patents, trade secrets, and/or know-how, that is conceived, reduced to practice, or
otherwise developed by Codexis or its Affiliates, either solely or jointly with a Third Party, during the Term that relate solely to the Codexis Technology. 

1.8    “Codexis Process” shall mean the process for the transformation of Substrate to
Product using Codexis Enzyme, as covered by those patents and patent applications listed in Exhibit 1.8. 

1.9    “Codexis Technology” shall mean (a) Codexis Enzyme, (b) Codexis Process,
and (c) Codexis Inventions, including, in each case, any intellectual property rights embodied therein. 

1.10    “Commercial Materials” shall have the meaning set forth in
Exhibit 4.1. 
 1.11    “Confidential Information” shall mean any
information of a confidential and/or proprietary nature, including without limitation the data, results, inventories, know-how, processes, machines, methods, developments, compositions of matter, inventions,
invention disclosures, patent applications, proprietary materials and/or techniques, economic information, business or research strategies, purchase orders (and any information included therein), trade secrets, or other information of any type or
kind, and material embodiments thereof, disclosed by a Party to the other Party. 

  
 -2- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 EXECUTION VERSION 
  

 1.12    “Control” shall mean, with respect
to an item, information or intellectual property right, possession of the ability, whether arising by ownership or license, to grant a license or sublicense as provided for herein under such item, information or intellectual property right without
violating the terms of a written agreement with any Third Party. 
 1.13    “Customer
Technology” shall mean intellectual property rights licensed from third parties or developed solely by Customer with respect to (a) the Product and derivatives thereof, (b) the processes to make the Product; and (c) uses
of the Product, including, in each case, any intellectual property rights embodied therein. 

1.14    “Enzyme Specification” shall have the meaning set forth in Section 3.5(e).

 1.15    “Facility” shall mean the facility/facilities of Codexis or its Third Party
Contractor(s) where the Codexis Enzyme are manufactured. 
 1.16    “Firm Order” shall
mean a binding commitment in writing, made by Customer, to purchase a specified amount of Codexis Enzyme from Codexis. 

1.17    “First Health Registration” shall have the meaning set forth in Section 8.3(a)
(License Obligations). 
 1.18    “Government Authority” shall mean any supranational,
national, regional, state or local government, court, governmental agency, authority, board, bureau, instrumentality, regulatory body, or other government entity, including without limitation any of the foregoing that is involved in the granting of
approvals, licenses, registrations, or authorizations. 
 1.19    “Health Registration”
shall mean a New Drug Application or [***] prepared in conformance with applicable Agency regulations for filing with the Agency for marketing authorization of Product. 

1.20    [***] shall mean, with respect to any country in the Territory, [***]. 

1.21    “Pre-Commercial Materials” shall have the
meaning set forth in Exhibit 4.1. 
 1.22    “Product” shall mean
vibegron [***]. 
 1.23    “Quarter” shall mean each of the three consecutive calendar
months ending March 31, June 30, September 30 and December 31. 

1.24    “Substrate” shall mean [***]. 

1.25    “Term” shall have the meaning set forth in Section 9.1 (Term). 

  
 -3- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 EXECUTION VERSION 
  

 1.26    “Territory” shall mean all of the
countries of the world excluding Brunei, Cambodia, Hong Kong, Indonesia, Japan, Korea, Laos, Malaysia, Myanmar, Philippines, Singapore, Taiwan, Thailand and Vietnam. 

1.27    “Third Party” (and with its correlative meaning, “Third
Parties”) shall mean any party other than Codexis, Customer, or an Affiliate of either Codexis or Customer. 
  

	2.	LICENSE FOR PRODUCT 

 2.1    License for Product.
Customer represents and warrants to Codexis that it Controls the Product (with respect to the manufacturing and/or sale of the Product in the Territory) and that it is a licensee of and possesses all required intellectual property rights from MSD
relating to the manufacture and sale of the Product in the Territory. If, at any time, Customer ceases to Control the Product (with respect to the manufacturing and/or sale of the Product in the Territory) or be authorized to manufacture and sell
Product in all of the Territory, this Agreement shall terminate. If, at any time, Customer ceases to Control the Product and be authorized to manufacture and sell Product in any portion of the Territory, then with respect to such portion(s) of the
Territory in which Customer ceases to Control the Product or be authorized to manufacture and sell Product, this Agreement shall terminate 
  

	3.	ENZYME SUPPLY 

 3.1    Codexis Enzyme Supply. Subject
to the terms and conditions of this Agreement, Codexis shall supply Codexis Enzyme on a non-exclusive basis to Customer, and Customer shall purchase from Codexis all of its requirements for Codexis Enzyme, for
use in the manufacture of Product by Customer for sale by or on behalf of Customer of such Product in the Territory during the Term. [***]. 

3.2    Terms and Conditions. All supply of Codexis Enzyme by Codexis to Customer shall be subject to the
terms and conditions of this Agreement. Any terms of any Purchase Order or acknowledgement given or received which are inconsistent with this Agreement given by either Party shall have no effect, and such terms are hereby excluded and rejected. 

3.3    Restricted Rights. All Codexis Enzyme transferred to Customer under this Agreement are and shall be
solely used for the manufacture of Product by Customer for sale by or on behalf of Customer (whether as Product or as incorporated in a formulated drug product) in the Territory in accordance with the terms and conditions of this Agreement. Product
manufactured by Customer using Codexis Enzyme and pursuant to the license granted herein may not be resold by or for Customer with intended use or distribution (whether as Product or as incorporated in a formulated drug product) outside of the
Territory. Any distribution, use, or other exploitation of Codexis Enzyme not in accordance with this Agreement shall be considered to be unlicensed and are hereby 

  
 -4- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 EXECUTION VERSION 
  

 
prohibited. Customer shall not transfer any Codexis Enzyme to any Third Party (except to a contract manufacturing organization using Codexis Enzyme to manufacture Product solely by or for
Customer for sale by or on behalf of Customer in the Territory, in which event Customer shall ensure that such contract manufacturing organization complies with Customer’s obligations under this Section 3.3 (Restricted Rights),
Section 3.9 (Use of Codexis Enzymes, Section 8.1(a) (Ownership by Codexis) and Article 6 (CONFIDENTIALITY). Customer shall not manufacture Codexis Enzyme or acquire Codexis Enzyme from any Third Party. 

3.4    Forecasts. Within [***] at the beginning of each Quarter during the Term, Customer shall provide
Codexis in writing (e-mail is acceptable) a good faith forecast reflecting Customer’s requirements, if any, for Codexis Enzyme for each of the following [***] by setting forth the quantities of Codexis
Enzyme to be supplied, broken down by Quarter. All projected order dates, quantities and shipping dates set forth in the forecasts delivered pursuant to this Section 3.4 shall be binding on Customer in respect of the requirements set forth for
the [***] immediately following the delivery of each such forecast. 
 3.5    Orders. 

(a)    Purchase Orders. At least [***] prior to the beginning of each Quarter during the Term, Customer
shall place a Firm Order for its requirements of Codexis Substance for such Quarter. Customer may also place a Firm Order at any time during the Term of this Agreement; provided, that such Firm Order is submitted at least [***] prior to the
earliest delivery date set forth in such Firm Order. Each Firm Order shall specify the following: 
  

	 	1.	Quantity of Codexis Enzyme ordered; 

  

	 	2.	The price of the Codexis Enzyme ordered per Exhibit 4.1; 

  

	 	3.	The required delivery date(s); 

  

	 	4.	The ship-to address; 

  

	 	5.	The specific packaging amount; 

  

	 	6.	Shipping conditions. 

 (b)    Subject to the terms and conditions of
this Agreement, Codexis shall accept such Firm Orders from Customer for each Codexis Enzyme; provided, that Codexis shall not be obligated to accept a Firm Order for Codexis Enzyme for any particular Quarter to the extent that the quantity of
Codexis Enzyme ordered for delivery in such Quarter exceeds [***] of the quantity of Codexis Enzyme forecasted for such month in accordance with Section 3.4 (Forecasts); provided, however, that Codexis shall use commercially
reasonable efforts to fulfill orders for such excess quantities from available supplies, taking into account Codexis’ own use, distribution and other obligations. Codexis shall communicate to Customer any potential manufacturing or supply
challenges of which it is aware at the time of receipt of the Firm Order, which are reasonably expected to impact Codexis’ ability to fulfill such Firm Order. 

  
 -5- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 EXECUTION VERSION 
  

 (c)    Minimum Order Quantities. Each Firm Order shall be
for the minimum purchase quantity(ies) agreed upon between Codexis and Customer with respect to a Calendar Year as agreed upon in accordance with Exhibit 4.1. 

(d)    Form of Order. All Firm Orders shall be governed by the terms and conditions of this Agreement and
any term or condition set forth in a Firm Order that would materially amend or supplement the terms and conditions of this Agreement is rejected and without effect. All of Customer’s orders for Codexis Enzyme shall be made pursuant to such
written Firm Order form and shall provide for shipment in compliance with Section 3.6 (Delivery and Storage of Codexis Enzymes). Codexis shall promptly notify Customer of its acceptance or rejection of a Firm Order, and shall use commercially
reasonable efforts to do so within [***] from receipt of such Firm Order. 
 (e)    Enzyme Specification.
For Codexis Enzyme that is being supplied to Customer for manufacture of pre-commercial quantities of Product, the [***] Certificate of Analysis attached as Exhibit 3.5(d) shall apply but is
not guaranteed. Prior to the supply of Codexis Enzyme that will be used in the manufacture of Product intended to be sold commercially, the Parties will agree in good faith on final specifications for the Codexis Enzyme to be delivered and shall
attach such final specifications as a replacement Exhibit 3.5(d) (the “Enzyme Specification”). The Parties may amend the Enzyme Specification for Codexis Enzyme hereunder from time to time by mutual written
agreement. Codexis Enzyme shall be manufactured in accordance with appropriate quality controls, as may be mutually agreed upon by the Parties in a separate written Quality Agreement. 

3.6    Delivery and Storage of Codexis Enzyme. Subject to Section 3.5 (Orders), Codexis shall deliver
to Customer the amount of Codexis Enzyme specified in each Firm Order no later than the date(s) specified therein. All Codexis Enzyme shall be shipped by Codexis [***] (Incoterms 2010) at [***] (or such [***] referenced in Section 3.11
(Supply)), and risk of loss shall pass to Customer upon such delivery. Codexis shall ship Codexis Enzyme under appropriate packaging and storage conditions. Codexis shall provide any documentation required for shipment of Codexis Enzyme (e.g. MSDS,
COA for each batch, and shelf life/retesting period for such batch). Customer shall store, handle and maintain the Codexis Enzyme in accordance with storage instructions as determined by Codexis [***], which storage instructions may be amended from
time to time by Codexis in writing. Customer shall bear any and all costs from failure to comply with such storage instructions, including without limitation any payments required for additional quantities of Codexis Enzyme purchased by Customer due
to such failure. 
 3.7    Inspection. Prior to shipment of any Codexis Enzyme, Codexis and/or any Third
Party referenced in Section 3.11 (Supply) shall test and inspect such shipment to ensure compliance with the applicable Enzyme Specification. Upon receipt of shipment of Codexis Enzyme, Customer shall, either directly or through a contract
manufacturing organization, inspect such Codexis Enzyme for compliance with the Enzyme Specification for such Codexis Enzyme corresponding to such shipment. Customer shall inform Codexis of the result of the inspection, including any claim with
respect to all or part of a shipment, 

  
 -6- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 EXECUTION VERSION 
  

 
in writing within [***] after the delivery of such shipment of Codexis Enzyme. In the event that Codexis receives a written notice of claim from Customer, which notice must include sufficient
detail identifying the basis for claim, the Parties shall determine if such claim is proper pursuant to the dispute resolution mechanism set forth in Section 3.8 (Disputes) and shall enter into good faith discussions regarding supply of
replacement quantities of Codexis Enzyme during the dispute resolution process. If Customer fails to notify Codexis in writing of a claim within such [***] period, Customer’s right to submit a claim for the shipment for any basis that would
have been discoverable through an inspection will be deemed to have been waived, notwithstanding any right of Customer to submit a claim to Codexis in connection with latent defects. 

3.8    Disputes. If Codexis disputes Customer’s conclusion to submit a claim with respect to all or
part of any shipment of any Codexis Enzyme as set forth in Section 3.7 (Inspection), Codexis shall notify Customer within [***] after receipt of Customer’s written notice of such rejection. Such dispute shall be resolved by a Third Party
within [***] of such notice by Codexis. Such Third Party shall have expertise in the area of biocatalysis, the identity of whom shall be mutually agreed upon by the Parties, and the appointment of whom shall not be unreasonably delayed or
conditioned by either Party. The determination of such Third Party with respect to all or part of any shipment of any Codexis Enzyme shall be final and binding upon the Parties. The Third Party’s scope of review and decision shall be limited to
the claim with respect to the shipment or part thereof, and Codexis’ responses thereto. For the avoidance of doubt, if such Third Party determines that the reasons given by Customer in submitting a claim with respect to the shipment or part
thereof were: (x) proper, then at Codexis’ election, Codexis shall replace such shipment or provide a full refund or credit, and (y) not proper, then no refund or credit shall be due to Customer. The fees and expenses of such Third
Party shall be paid by [***.] Each of Codexis and Customer shall bear their own fees and expenses, including and legal or consultant fees, incurred under this Section 3.8. 

  
 -7- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 EXECUTION VERSION 
  

 3.9    Use of Codexis Enzymes. Except as expressly set
forth in this Agreement, Customer will not, and will not allow any Third Party to, without the prior written consent of Codexis, (a) extract information from, reverse engineer, deconstruct, disassemble, sequence or in any way determine, or
attempt to extract information from, reverse engineer, deconstruct, disassemble, sequence or in any way determine, the biological, chemical or physical structure or composition of any of the Codexis Enzyme or its components; (b) copy, alter,
immobilize, stabilize, add to, alter, modify or otherwise design or create any derivative of Codexis Enzyme or its components; or (c) transfer any Codexis Enzyme or its respective components, or sequence information pertaining thereto, to a
Third Party (except as expressly provided for under Section 3.3 (Restricted Rights) or Section 8.2 (License to Codexis Technology)) or otherwise sublicense or subcontract any of its rights or obligations under this Agreement to any Third
Party. This Agreement does not permit Customer to use the Codexis Enzyme to treat human subjects. For the avoidance of doubt and without limiting any other remedies Codexis may have, to the extent Customer breaches this Section 3.9, Customer
acknowledges and agrees that Codexis owns any and all intellectual property rights that arise from such breach and Customer hereby exclusively assigns to Codexis all right, title and interest in, to and under such intellectual property that Customer
has or may thereafter acquire as a result of such breach. Customer hereby agrees to take or cause to be taken all actions as Codexis deems necessary or desirable in order for Codexis to obtain the full benefits of the assignment described in the
immediately preceding sentence and the transactions contemplated thereby. 
 3.10    Third Party
Contractors. Codexis shall have the right at any time to satisfy its supply obligations to Customer under this Agreement either in whole or in part through arrangements with Third Parties engaged to perform services or supply facilities or goods
in connection with the manufacture, testing, and/or packaging of Codexis Enzyme; provided, that Codexis shall remain responsible for the actions of such Third Parties and for compliance with its obligations under this Agreement. 

3.11    Supply. 

(a)    Efforts by Codexis. Codexis shall use all commercially reasonable efforts to supply Codexis Enzyme in
accordance with this Article 3; provided, however, that if Codexis encounters any issues in respect of supply or delivery, including but not limited to feasibility issues or scale-up issues,
Codexis shall notify Customer and [***]. 
 (b)    [***] 

3.12    Relationship. As between the Parties, Customer shall be solely responsible for (i) the
production of Product using Codexis Enzyme, (ii) converting Substrate to Product using Customer’s technology, and (iii) distributing, selling and marketing Product in the Territory. 

  
 -8- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 EXECUTION VERSION 
  

	4.	PAYMENT; TAXES 

 4.1    Pricing. Customer shall pay
Codexis for Codexis Enzyme delivered hereunder as established in accordance with Exhibit 4.1 of this Agreement. In addition, Customer shall pay any and all insurance, shipment, taxes (as further described in Section 4.4
(Taxes)) or other costs incident to the transfer or shipment of the Codexis Enzyme. 
 4.2    Invoicing.
All invoices shall be sent to Customer’s address for notices hereunder or such other address as designated by Customer in writing, and each such invoice shall state Customer’s aggregate and unit prices for the Codexis Enzyme, and shall
separately itemize any insurance, taxes or other costs incident to the transfer or shipment initially paid by Codexis but to be borne by Customer hereunder. In the event of any discrepancy, Customer shall inform Codexis in writing within [***] of
receipt of a particular shipment, specifying the shipment, the Firm Order number, and the exact nature of the discrepancy between the order and the shipment, or the exact nature of the discrepancy in the shipping or other charges, as applicable,
otherwise such shipment and applicable charges shall be deemed correct. 
 4.3    Payment. Customer shall
make full payment to Codexis for all Codexis Enzyme shipped hereunder no later than [***] from the date of Codexis’ invoice. Any payment under the terms and conditions of this Agreement made after such [***] period shall bear compounding
interest beginning one (1) day after the expiration of such [***] period and shall continue to accrue such interest until such payment is made at a rate equal to the [***]. 

4.4    Taxes. Customer shall be responsible for all federal, state and local taxes, or charges in lieu of
taxes, now or hereafter imposed on the sale or use of the Codexis Enzyme, except for income or other similar taxes imposed on Codexis. Any taxes for which Customer is responsible hereunder shall be charged to Customer and shall be in addition to the
prices set forth in this Article 4 (PAYMENT; TAXES). 
 4.5    Method. An payments made under this
Agreement shall be made by direct wire transfer of United States Dollars in immediately available funds in the requisite amount to such bank account as Codexis may from time to time designate by written notice to Customer. 

 

	5.	GOVERNMENTAL LAW AND REGULATIONS 

 5.1    Applicable
Law. Codexis’ and Customer’s obligations hereunder shall be subject to all Applicable Law. Codexis shall secure such permits and licenses necessary, at its sole expense, for the manufacture and sale of Codexis Enzyme hereunder, unless
otherwise agreed by the Parties in writing. 
 5.2    Regulatory Filings. As between the Parties, Customer
and its Affiliates will be responsible for filing any regulatory approval application in connection with Product, at their own cost. 

  
 -9- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 EXECUTION VERSION 
  

 5.3    Records. Codexis shall maintain complete, true, and
accurate books, records, test and laboratory data, reports, and all other information relating to Codexis Enzymes, including the manufacturing data and technical records pertaining to the methods, facilities, and equipment used for processing, in
accordance with Applicable Laws and as is reasonably necessary to support regulatory filings by Customer with respect to the Product. Codexis shall store all such records and information for a period of at least [***] from the relevant Codexis
Enzyme manufacturing date or longer if required under Applicable Laws, after which date Codexis may dispose of such records upon providing reasonable prior written notice of such destruction to allow Customer to request such records. 

5.4    Regulatory Obligations. Customer shall be solely responsible for preparation and submission of
applications to Agencies regarding the Product. Customer will advise Codexis of document requirements in support of such applications by Customer. Codexis will, at Customer’s expense at Codexis’ then-current rates agreed upon by the
Parties, use its commercially reasonable efforts to provide documents and additional information needed for such applications, and to cooperate with and assist Customer in preparation and submission of such applications to the FDA (and other
Agencies, as appropriate). All such applications to Agencies and related filings by Customer shall be the sole and exclusive property of Customer, as applicable. Customer shall be solely responsible for all contacts and communications with any
Agencies with respect to all matters relating to the Product. At the request of Customer, Codexis shall make appropriate personnel reasonably available for meetings with Agencies related to manufacturing of Codexis Enzymes and the related processing
of the Product. 
 5.5    Regulatory Notifications. Codexis shall notify Customer immediately, and in no
event later than [***], after receiving any contact or communication from any Regulatory Authority that in any way relates to the Products. Codexis shall advise Customer no later than the next day that is not a Saturday, Sunday, or federal or state
holiday if an authorized agent of any Agencies or any other regulatory body plans to visit the Facility solely in relation to the Products for Customer, and/or makes an inquiry regarding manufacturing of Codexis Enzymes for use in processing
Products for Customer or regarding any part of the Facility that is used in manufacturing of Codexis Enzymes for use in processing of Products for Customer. Customer shall have the right to be present at any visit relating to Products for Customer
and to review in advance and comment on any response to the communication or investigation submitted by Codexis. Codexis shall cooperate fully with such Regulatory Authority and with Customer in providing the information needed for any such
communication. Codexis shall provide to Customer copies of any document delivered by such Regulatory Authority or regulatory body as a result of such visit. If an authorized agent of any Regulatory Authority or any other regulatory body visits the
Facility in connection with another product or another part of the Facility and such visit results in a finding or other action that could materially and adversely affect Codexis’ production of Codexis Enzyme under this Agreement, then Codexis
shall notify Customer as soon as practicable and shall provide Customer with information concerning Codexis’ response to such finding or action. Customer shall retain the right to amend Codexis’ response to a Regulatory Authority solely in
relation to the Product. 

  
 -10- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 EXECUTION VERSION 
  

 5.6    Audits. During the Term and during the period in
which Codexis is supplying the Codexis Enzymes, Customer or its authorized representatives reasonably acceptable to Codexis at Customer’s cost for the purposes of audit may visit the Facilities of Codexis or its Third Party Contractors where
the Codexis Enzymes are being manufactured, during normal business hours. The detailed scope of audit shall be communicated to Codexis at least [***] prior to the requested date of audit and the Parties shall work in good faith to schedule a
mutually agreeable date for such audit. Any such audit shall be conducted in accordance with Codexis’ then-current policies and without material disruption to Codexis’ or Codexis’ Third Party Contractor activities. Customer shall be
entitled to conduct an audit hereunder once in any [***] period during the term of this Agreement, upon reasonable notice during regular business hours for a period not to exceed [***]; provided, however, that Customer shall be entitled to conduct
audits following issuance of reports delivered by Agencies to Codexis pertaining to manufacturing of Codexis Enzymes for use in processing Products for Customer or the occurrence of other events which are likely to adversely affect Customer’s
processing of Products as frequently as requested by Customer at reasonable times and for reasonable duration (which may not exceed [***]) until Codexis has corrected such deficiencies. Upon request, Customer may conduct additional audits, provided
that Customer shall reimburse Codexis for reasonable time and expenses incurred by Codexis in connection with such audits. 
  

	6.	CONFIDENTIALITY 

 6.1    In General. In connection
with this Agreement each Party may provide to the other Party, Confidential Information. Codexis Technology shall constitute the Confidential Information of Codexis. 

6.2    Non-Disclosure and
Non-Use. The receiving Party shall maintain the Confidential Information of the disclosing Party in confidence, shall not disclose such Confidential Information to any Third Party, and shall not use such
Confidential Information for any purpose except as expressly permitted under the terms and conditions of this Agreement. Notwithstanding the previous sentence, the receiving Party may disclose the Confidential Information of the disclosing Party
solely on a “need to know basis” to its Affiliates and its officers, directors, employees, advisors, legal counsel, contractors and agents, and independent legal counsel, each of whom prior to disclosure must he hound by obligations of
nondisclosure and non-use no less restrictive than the obligations set forth in this Article 6 (CONFIDENTIALITY); provided, however, that, in each of the above situations, the receiving
Party shall remain responsible for any failure by any person or entity who receives Confidential Information pursuant to this Section 6.2 to treat such Confidential Information as required under this Article 6 (CONFIDENTIALITY). The
receiving Party shall take the same degree of care that the receiving Party uses to protect its own confidential and proprietary information of a similar nature and importance, but in no event shall such care be less than reasonable care. 

  
 -11- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 EXECUTION VERSION 
  

 6.3    Exceptions. The obligations of non-disclosure and non-use under Section 6.2 (Non-Disclosure and Non-Use) will not apply
as to particular Confidential Information of a disclosing Party to the extent that such Confidential Information: (a) is at the time of receipt, or thereafter becomes, through no fault of the receiving Party or its Affiliates, published or
publicly known or available; (b) is known by the receiving Party or its Affiliates at the time of receiving such information, as evidenced by competent records; (c) is hereafter furnished to the receiving Party or its Affiliates by a Third
Party without breach of a duty to the disclosing Party; or (d) is independently discovered or developed by the receiving Party or its Affiliates without use of, application of, access to, or reference to Confidential Information of the
disclosing Party, as evidenced by competent records. 
 6.4    Disclosure Required by Law. Disclosure of
Confidential Information shall not be precluded if such disclosure (a) is in response to a valid order, or required under the regulations, of a court or other governmental body; or (b) is required by Applicable Law; provided,
however, that the receiving Party, to the extent practicable, first has given reasonable prior notice to the disclosing Party and at the disclosing Party’s request, the receiving Party cooperates with the disclosing Party’s efforts,
as applicable, to obtain a protective order limiting the extent of such disclosure and requiring that the Confidential Information so disclosed be used only for the purposes for which such order was issued or as required by such Applicable Law. Any
disclosure made pursuant to this Section 6.4 shall not affect the confidential nature of the disclosed Confidential Information (except to the extent the disclosure was made publicly available, such as but not limited to filings with the United
States Securities and Exchange Commission, in which case such disclosed Confidential Information shall no longer be deemed confidential). 

6.5    Remedies. The receiving Party agrees that its obligations under this Article 6 (CONFIDENTIALITY) are
necessary and reasonable to protect the disclosing Party’s business interests and that the unauthorized disclosure or use of Confidential Information of the disclosing Party will cause irreparable harm and significant injury, the degree of
which may be difficult to ascertain. The receiving Party further acknowledges and agrees that in the event of any actual or threatened breach of this Article 6 (CONFIDENTIALITY), the disclosing Party may have no adequate remedy at law and,
accordingly, that the disclosing Party will have the right to seek an immediate injunction, without an obligation to post a bond or any similar security, enjoining any breach or threatened breach of this Article 6 (CONFIDENTIALITY), as well as the
right to pursue any and all other rights and remedies available at law or in equity for such breach or threatened breach. 

6.6    Agreement Terms; Press Release. The existence of, and the terms and conditions of, this Agreement
shall be Confidential Information of each of the Parties, and subject to the terms of this Article 6 (CONFIDENTIALITY); provided, however, that (a) each Party may disclose this Agreement, in confidence, (i) to [***],
(ii) to legal, scientific, 

  
 -12- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 EXECUTION VERSION 
  

 
regulatory and financial advisors and (iii) in connection with any proposed or actual transactions involving the disclosing Party in the form of mergers, offerings, acquisitions, fundings
and investments; and (b) each Party may disclose this Agreement, in its entirety or with portions redacted, as may be required by Applicable Law. Notwithstanding the foregoing, upon or after the execution of this Agreement, the Parties may:
(c) issue a press release relating generally to their entry into this Agreement, provided, however, that such press release has been agreed to by both Parties prior to issuance; and (d) list the other Party’s name and/or
logo on its website or in promotional materials, and may otherwise disclose that the other Party is a contracting party of such Party. 

6.7    Survival. All obligations of non-disclosure and non-use imposed pursuant to the terms and conditions of this Article 6 (CONFIDENTIALITY) shall survive expiration or termination of this Agreement and continue in full force and effect for a period of [***]
after the effective date of such expiration or such termination. 
  

	7.	REPRESENTATIONS AND WARRANTIES 

 7.1    Representations by
Each Party. Each Party represents and warrants that as of the Effective Date: (a) it is duly organized and validly existing under the laws of the jurisdiction of its incorporation and has MI corporate power and authority to enter into this
Agreement; (b) it has taken all corporate actions necessary to authorize the execution and delivery of this Agreement and the performance of its obligations under this Agreement; and (c) the performance of its obligations under this
Agreement do not conflict with, or constitute a default under, its charter documents, any contractual obligation of such Party or any court order. 

7.2    Disclaimer of Warranties. EXCEPT AS SPECIFICALLY SET FORTH IN THIS ARTICLE 7 (REPRESENTATIONS AND
WARRANTIES), NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY, ANY WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE OR USE, OR ANY OTHER SIMILAR STATUTORY
WARRANTY. EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL IMPLIED WARRANTIES. 
  

	8.	INTELLECTUAL PROPERTY 

 8.1    (a) Ownership by
Codexis. As between the Parties, subject only to the license set forth in Section 8.2 (License to Codexis Technology), Codexis shall retain and own all right, title and interest in, to and under the Codexis Technology, and Codexis shall
have the right, but not the obligation, to file applications for, and to control the prosecution and maintenance of, the Codexis Technology and to enforce all rights therein. For the avoidance of doubt, Codexis has no rights to Customer Technology.

 (b)    Ownership by Customer. As between the Parties, Customer shall retain and own all right, title
and interest in, to and under the Customer Technology, and 

  
 -13- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 EXECUTION VERSION 
  

 
Customer shall have the right, but not the obligation, to file applications for, and to control the prosecution and maintenance of, the Customer Technology and to enforce all rights therein. For
the avoidance of doubt, Customer has no rights to improve or modify the Codexis Technology. 
 8.2    License
to Codexis Technology. Subject to the terms and conditions of this Agreement, Codexis hereby grants to Customer a non-exclusive, non-transferrable, non-sublicensable (except as provided below), worldwide license under the Codexis Technology to use and import (but not to make, have made, improve, have improved, modify, have modified, sell, or have sold) Codexis
Enzyme in order to make, have made, use, import, sell and have sold Product in the Territory, This license does not grant Customer any rights under Codexis Technology to use and import Codexis Enzyme in order to make, have made, use, import, sell
and have sold Product (whether as Product or as a formulated drug product) for resale by third parties (including, without limitation, [***]) for sale outside of the Territory. Until the satisfaction by Customer of all of its obligations under
Section 8.3 (License Obligations), the license shall not be transferable, and shall not be sub-licensable except: a) to Affiliates of Customer and to contract manufacturing organizations manufacturing
Product for Customer and its Affiliates; and, b) with regard to the Product formulated as a drug product, to third parties conducting clinical research and/or drug product testing on behalf of the Customer and/or its Affiliates that is necessary for
the regulatory approval in the Territory. After the satisfaction by Customer of all of its obligations under Section 8.3 (License Obligations), the license shall be fully transferrable to a successor to Customer’s rights under this
Agreement and its agreement with MSD relating to the Product and sublicensable. 
 8.3    License
Obligations. In consideration for the license granted by Codexis under Section 8.2 (License to Codexis Technology), Customer agrees to the following payment and purchase obligations: 

(a)    Upon Customer receiving the first approval of a Health Registration for Product in any of the United States,
Europe or Canada (“First Health Registration”), Customer shall pay Codexis a one-time, non-refundable,
non-creditable milestone payment of US$500,000. Customer shall notify Codexis in writing of Customer’s receipt of such First Health Registration, and Codexis shall invoice Customer for such milestone
payment. Such payment shall be made by Customer to Codexis within [***] from the date of such invoice from Codexis. 

(b)    [***.] 

(c)    [***.] 

8.4    No Other Rights. Except for the rights expressly granted in this Agreement, no right, title or
interest of any nature whatsoever is or shall be granted whether as a result of sale or transfer, by implication, estoppels, reliance or otherwise, with respect to the Codexis Technology. All rights with respect to Codexis Technology that are not
specifically granted in this Agreement are reserved to Codexis. 

  
 -14- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 EXECUTION VERSION 
  

	9.	TERM AND TERMINATION 

 9.1    Term. The term of this
Agreement shall commence on the Effective Date through six (6) years from the date of First Health Registration, unless earlier terminated in accordance with Sections 2.1 (License for Product), 9.2 (Termination for Convenience),
9.3 (Termination for Cause) or 9.4 (Termination for Insolvency) (the “Term”), 

9.2    Termination for Convenience. 

(a)    At any time after the Effective Date, but before [***], Customer may terminate this Agreement upon written
notice to Codexis. 
 (b)    At any time (1) on or after the [***] and (ii) the satisfaction by
Customer of all of its obligations under Section 8.3 (License Obligations), Customer may terminate this Agreement upon written notice to Codexis. 

9.3    Termination for Cause. Either Party may terminate this Agreement upon sixty (60) days written
notice to the other Party if the other Party materially breaches any obligation set forth herein, which breach has not been cured within sixty (60) days after receipt of written notice of such breach from the
non-breaching Party, or within such additional cure period as the non-breaching Party may so authorize in writing. in the event of a
non-curable breach, the non-breaching Party shall be entitled, in the non-breaching Party’s sole discretion, to immediately
terminate this Agreement in its entirety. A failure by Customer to make payment hereunder shall be considered a material breach unless cured within [***] of receipt of written notice of such non-payment. 

9.4    Termination for Insolvency. To the extent permitted under Applicable Law, a Party may terminate this
Agreement upon [***] written notice to the other Party if the other Party becomes insolvent, makes a general assignment for the benefit of creditors, files a voluntary petition in bankruptcy, suffers or permits the appointment of a receiver for its
business or assets, becomes subject to any proceeding under any bankruptcy or any insolvency law, whether domestic or foreign, or has wound up or liquidated its business voluntarily or otherwise. 

9.5    Consequences of Expiration or Termination. 

(a)    Licenses. Upon expiration or termination of this Agreement by either Party for any reason, the
license granted under Section 8.2 shall terminate and Customer shall cease use of any and all Codexis Technology. 

(b)    Return of Materials. Upon expiration or termination of this Agreement by either Party for any reason,
each Party shall promptly return, or destroy and provide written certification of such destruction by a duly authorized officer of such Party, 

  
 -15- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 EXECUTION VERSION 
  

 
any and all Confidential Information of the other Party in such first Party’s possession or control at the time of such expiration or termination and Customer shall promptly return to all
unused supplies of Codexis Enzyme, [***]. 
 (c)    Accrued Liability. Expiration or termination of this
Agreement for any reason shall not release either Party hereto from any liability which at the time of such termination has already accrued to the other Party prior to such time. Such expiration or termination will not relieve a Party from accrued
payment obligations or from obligations which are expressly indicated in this Agreement to survive expiration or termination of this Agreement. 

9.6    Survival. In addition to any sections of this Agreement which by their terms survive expiration or
termination of this Agreement, the following Articles and Sections of this Agreement shall survive its expiration or termination: Articles 1 (DEFINITIONS), 4 (PAYMENT; TAXES), 5 (GOVERNMENTAL LAW AND REGULATIONS),
6 (CONFIDENTIALITY), 10 (INDEMNIFICATION) and 11 (MISCELLANEOUS), and Sections 3.2 (Terms and Conditions), 3.3 (Restricted Rights), 3.8 (Disputes) (if applicable), 3.9 (Use of Codexis Enzyme),
3.12 (Relationship), 7.2 (Disclaimer of Warranties), 8.1 (Ownership of Codexis), 8.4 (No Other Rights), 9.4 (Termination for Insolvency) and 9.5 (Consequences of Expiration or Termination). All obligations to make
payments to Codexis shall survive expiration or termination of this Agreement. 
  

	10.	INDEMNIFICATION 

 10.1    Indemnification by [***].

 10.2    Indemnification by [***]. 

10.3    Insurance. Customer agrees to carry insurance in coverage and amounts reasonable and customary for a
company of similar size and in the same industry as Customer. Codexis agrees to carry insurance in coverage and amounts reasonable and customary for a company of similar size and in the same industry as Customer. 

 

	11.	MISCELLANEOUS 

 11.1    Further Assurances. From time
to time on and after the Effective Date, each Party shall at the reasonable request of the other Party: (a) deliver to the other Party such records, data, or other documents; (b) execute, and deliver or cause to be delivered, all
assignments, consents, documents or further instruments of transfer or license; and (c) take or cause to be taken all other actions as such other Party may reasonably deem necessary or desirable in order for such Party to obtain the full
benefits of this Agreement and the transactions contemplated hereby; each to the extent as required under the provisions of this Agreement. 

11.2    Limitation of Liability. EXCEPT FOR BREACHES OF ARTICLE 6 (CONFIDENTIALITY), SECTION 3.10
(Third Party Contractors) OR 

  
 -16- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 EXECUTION VERSION 
  

 
INDEMNIFICATION PURSUANT TO ARTICLE 10 (INDEMNIFICATION), IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR INCIDENTAL, CONSEQUENTIAL, INDIRECT, PUNITIVE, EXEMPLARY, OR SPECIAL DAMAGES OF THE OTHER
PARTY ARISING OUT OF OR RELATED TO THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY, WHETHER FORESEEABLE OR NOT. FURTHERMORE, IN NO EVENT SHALL CODEXIS BE LIABLE TO CUSTOMER FOR ANY CLAIM FOR DAMAGES CUSTOMER SUFFERS UNDER THIS
AGREEMENT IN AN AMOUNT EXCEEDING [***], PROVIDED THAT NOTHING HEREIN SHALL BE APPLICABLE TO ACTS OF GROSS NEGLIGENCE, INTENTIONAL BREACH OF THE AGREEMENT OR WILLFUL MISCONDUCT, 

11.3    Governing Law. This Agreement shall be governed by, and construed and interpreted in accordance
with, the internal laws of the State of New York, without giving effect to any choice of law rule that would cause the application of the laws of any jurisdiction other than the internal laws of New York to the rights and duties of the Parties. The
Parties exclusively agree to resolve all disputes arising out of, relating to or in connection with this Agreement by arbitration conducted under the then-existing Commercial Arbitration Rules of the American Arbitration Association
(“AAA”). The arbitration will be conducted in New York, New York, USA before a single, neutral arbitrator chosen by mutual agreement of the Parties or, failing that agreement, within [***] after written notice demanding
arbitration, by the AAA. Any award rendered by the arbitrator will be final, conclusive and binding upon the Parties, and judgment thereon may be entered and enforced in any court of competent jurisdiction. The arbitrator shall determine the claim
of the Parties and render a final award in accordance with the substantive law of the State of New York, excluding the conflicts provisions of such law, and shall apply the New York Rules of Evidence. Nothing in this Agreement shall be deemed as
preventing a Party from seeking injunctive relief (or any other provisional remedy) from any court having jurisdiction over the Parties and the subject matter of the dispute as necessary to protect that Party’s name, Confidential Information,
trade secrets, know-how, or any other proprietary rights. For actions or proceedings for injunctive relief pursuant to Section 11.4, each of the Parties irrevocably agrees that any such action shall be
brought and determined in any New York State or federal court sitting in New York County, New York, and each of the parties hereby irrevocably submits to the exclusive jurisdiction of the aforesaid courts for itself and with respect to its property,
generally and unconditionally, with regard to any such action. 

  
 -17- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 EXECUTION VERSION 
  

 11.4    Injunctive Relief. Each Party agrees that its
obligations hereunder are necessary and reasonable to protect the other Party and its Affiliates, and expressly agrees that monetary damages could be inadequate to compensate the non-breaching Party (and its
Affiliates) for any breach of any covenant or agreement set forth herein. Each Party agrees and acknowledges that any such violation or threatened violation could cause irreparable injury to the other Party and its Affiliates and that, in addition
to any other remedies that may he available, in law, or otherwise, the non-breaching Party shall be entitled (on its own behalf and on behalf of its affiliates) to obtain injunctive relief against any
threatened breach of this Agreement or the continuation of any such breach without the necessity of proving actual damages. 

11.5    Force Majeure. Except for the payment of money, neither Party shall be held responsible for any
delay or failure in performance hereunder caused by strikes, embargoes, unexpected government requirements, civil or military authorities, acts of God, flood, earthquake, or by the public enemy or other causes reasonably beyond such Party’s
control and without such Party’s fault or negligence; provided, that the affected Party notifies the unaffected Party as soon as reasonably possible and resumes performance hereunder as soon as reasonably possible following cessation of
such force majeure event; provided, further, that no such delay or failure in performance shall continue for more than [***], In the event that a delay or failure in performance by a Party wider this Section 11.5 continues longer
than [***], the other Party may terminate this Agreement in accordance with the terms and conditions of Section 9.3 (Termination for Cause). 

11.6    Independent Contractors. The Parties are independent contractors. Nothing in this Agreement is
intended or will be deemed to constitute a partnership, agency or employer-employee relationship between the Parties. Neither Party will incur any debts or make any commitments for the other Party. 

11.7    Assignment. Except as expressly provided herein, neither this Agreement nor any interest hereunder
will be assignable or any other obligation delegable, by a Party without the prior written consent of the other Party. Either Party shall have the right to assign and otherwise transfer this Agreement in whole or in part without consent to an
Affiliate of such Party. Either Party may assign and otherwise transfer this Agreement in whole to a successor that acquires all or substantially all of its business or assets related to the subject matter of this Agreement by way of merger,
consolidation, other business reorganization, or the sale of stock or assets, but only with the prior written consent of the other Party, which authorization shall not be unreasonably conditioned, withheld or delayed; provided,
however, that it shall not be unreasonable for the Party to refuse to authorize any assignment or transfer by the other Party to a non-Affiliate [***]. This Agreement shall be binding upon successors
and permitted assigns of the Parties. Any assignment not in accordance with this Section 11.7 shall be null and void. Any permitted assignment or transfer of this Agreement shall not release the assigning or transferring Party from its
obligations under this Agreement except to the extent the Assignee expressly assumes all responsibilities and obligations associated with such assignment or transfer. 

  
 -18- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 EXECUTION VERSION 
  

 11.8    Notices. Any notice, report, communication, or
consent required or permitted by this Agreement shall be in writing and shall be sent (a) by prepaid registered or certified mail, return receipt requested; (b) by overnight express delivery service by a nationally recognized courier;
(c) via confirmed facsimile, followed within five (5) days by a copy delivered in accordance with this Section 11.8; or (d) via e-mail or pdf, with delivery receipt and read receipt
requested, addressed to the other Party at the address shown below or at such other address as such Party gives notice hereunder. Such notice will be deemed to have been given when delivered or, if delivery is not accomplished by some fault of the
addressee, when tendered. 
  

			
	If to Customer:	  	Urovant Sciences GmbH
		  	Viaduktstrasse 8, 4051 Basel, Switzerland
		  	Attn: Head of Global Transactions
		
	With a copy to:	  	Urovant Sciences, Inc.,
		  	320 West 37th Street, 5th Floor,
		  	New York, NY 10018
		  	Attn: Legal Department
		
	If to Codexis:	  	Codexis, Inc.
		  	200 Penobscot Drive
		  	Redwood City, California 94063
		  	USA
		  	Attn: President
		  	Facsimile: [***]
		
	With a copy to:	  	Codexis, Inc.
		  	200 Penobscot Drive
		  	Redwood City, California 94063
		  	USA
		  	Attn: General Counsel
		  	Facsimile: [***]

 11.9    Severability. If any provision of this Agreement is found by a
court to be void, invalid, or unenforceable, such provision shall be reformed to comply with Applicable Law or stricken if not so conformable, so as not to affect the validity or enforceability of this Agreement; provided, that no such
reformation or striking shall be effective if the result materially changes the economic benefit of this Agreement to either Party, If any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be void, invalid,
or unenforceable, and reformation or striking of such provision would materially change the economic benefit of this Agreement to either Party, the Parties shall modify such provision in accordance with Section 11.10 (Modifications; Waivers) to
obtain a legal, valid, and enforceable provision and provide an economic benefit to the Parties that most nearly effects the Parties’ intent on entering into this Agreement. 

  
 -19- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 EXECUTION VERSION 
  

 11.10    Modifications; Waivers. This Agreement may not be
altered, amended, supplemented, or modified in any way except by a writing signed by each Party. The failure of a Party to enforce any rights or provisions of this Agreement shall not be construed to be a waiver of such rights or provisions, or a
waiver by such Party to thereafter enforce such rights or provisions or any other rights or provisions hereunder. 

11.11    No Third Party Beneficiaries. This Agreement is neither expressly nor impliedly made for the
benefit of any party other than those executing it. 
 11.12    Interpretation. 

(a)    Captions and Headings. The captions and headings of clauses contained in this Agreement preceding the
text of the articles, sections, subsections, and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect on its interpretation or construction. 

(b)    Singular and Plural. All references in this Agreement to the singular shall include the plural where
applicable, and all references to gender shall include both genders and the neuter. 
 (c)    Articles,
Sections, and Subsections. Unless otherwise specified, references in this Agreement to any article shall include all sections, subsections, and paragraphs in such article; references in this Agreement to any section shall include all subsections
and paragraphs in such section; and references in this Agreement to any subsection shall include all paragraphs in such subsection. 

(d)    Days. All references to days in this Agreement shall mean calendar days, unless otherwise specified.

 (e)    Ambiguities. The Parties jointly drafted this Agreement. Ambiguities and uncertainties in this
Agreement, if any, shall not be interpreted against either Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist. 

11.13    Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an
original and all of which together shall constitute one instrument. For purposes of executing this Agreement, a facsimile (including a “portable document format” (“.pdf”) image delivered via email) copy of this
Agreement, including the signature pages, will be deemed an original. 

  
 -20- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 EXECUTION VERSION 
  

 11.14    Entire Agreement. The Parties acknowledge that
this Agreement, including, for clarity, the preamble, recitals and exhibits attached hereto, sets forth the entire agreement and understanding of the Parties as to the subject matter hereof, and supersedes all prior and contemporaneous discussions,
agreements, and writings with respect hereto with respect to the subject matter hereof. No trade customs, courses of dealing or courses of performance by the Parties shall be relevant to modify, supplement, or explain any term(s) used in this
Agreement. Each Party agrees and acknowledges that it has not relied on any information, data, or forecasts provided by the other Party, or discussions with the other Party, in the negotiation and execution of this Agreement. 

[Signature page follows] 

  
 -21- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 EXECUTION VERSION 
  

 IN WITNESS WHEREOF, Customer and Codexis have executed this Agreement by their
respective duly authorized representatives on the dates identified below but the Agreement shall become effective on the Effective Date. 
  

			
	CODEXIS, INC.
		
	By:	 	/s/ Michael Aldridge

			
		
	Name:	 	Michael Aldridge

			
		
	Title:	 	SVP Corporate Strategic Development

			
		
	Date:	 	Sept-12-2017

			
	
	UROVANT SCIENCES GMBH
		
	By:	 	/s/ Sascha Bucher

			
		
	Name:	 	Sascha Bucher

			
		
	Title:	 	Head of Global Transactions

			
		
	Date:	 	Sep 14, 2017

 [***] 

  
 -22- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 EXECUTION VERSION 
  

 [***] 

  
 -23- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 EXECUTION VERSION 
  

 Exhibit 1.8 

Codexis Process 
 [***] 

  
 -24- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 EXECUTION VERSION 
  

 Exhibit 3.5(d) 

Enzyme Specification 
  

			
	

	  	[***]

  
 -25- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. 

 EXECUTION VERSION 
  

 Exhibit 4.1 

Pricing for Codexis Enzyme 
 [***]

  
 -26- 

 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}]]